Primary cerebral blood flow deficiency and Alzheimer's disease: Shadows and lights

Journal of Alzheimer's Disease

Volumn 23, Issue 3, 2011, Pages 375-389

  Mazza, Marianna ^a   Marano, Giuseppe ^a   Traversi, Gianandrea ^a   Bria, Pietro ^a   Mazza, Salvatore ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alzheimer's disease; amyloid ; blood brain barrier; cerebral blood flow; nitric oxide; reactive oxygen species

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; CHOLINESTERASE INHIBITOR; CITICOLINE; CYANOCOBALAMIN; D 003; DONEPEZIL; FISH OIL; FOLIC ACID; GALANTAMINE; GENISTEIN; GINKGO BILOBA EXTRACT; GLYCEROPHOSPHORYLCHOLINE; IDEBENONE; LEVACECARNINE; MEMANTINE; OMEGA 3 FATTY ACID; PHOSPHATIDYLSERINE; POLICOSANOL; RIVASTIGMINE; SESAMIN; TACRINE;

ALZHEIMER DISEASE; ANOREXIA; BLOOD BRAIN BARRIER; BLOOD VESSEL INJURY; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN ISCHEMIA; BRAIN PERFUSION; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DIZZINESS; HEADACHE; HEMODYNAMICS; HUMAN; LIVER TOXICITY; METABOLIC PARAMETERS; MULTIINFARCT DEMENTIA; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 79951876424     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-090700     Document Type: Review

References (154)

1. Van Broeck B, Van Broeckhoven C, Kumar-Singh S (2007) Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic (Pubitemid 47123462)
2. Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, Nunomura A, Casadesus G, Harris PL, Siedlak SL, Perry G (2007) Vascular oxidative stress in Alzheimer disease. J Neurol Sci 15, 240-246. (Pubitemid 46856513)
3. Dede DS, Yavuz B, Yavuz BB, Cankurtaran M, Halil M, Ulger Z, Cankurtaran ES, Aytemir K, Kabakci G, Ariogul S (2007) Assessment of endothelial function in Alzheimer's disease: is Alzheimer's disease a vascular disease? J Am Geriatr Soc 55, 1613-1617. (Pubitemid 47508508)
4. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5, 347-360. (Pubitemid 38568496)
5. Niedermeyer E (2006) Alzheimer disease: caused by primary deficiency of the cerebral blood flow. Clin EEG Neurosci 37, 175-177. (Pubitemid 44222857)
6. Niedermeyer E (2007) Considerations of the ischemic basis and therapy of Alzheimer disease. Clin EEG Neurosci 38, 55-56. (Pubitemid 46696869)
7. Jellinger KA (2008) The pathology of "vascular dementia": a critical update. J Alzheimers Dis 14, 107-123. (Pubitemid 352039011)
8. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM (2008) Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. Stroke 39, 349-354. (Pubitemid 351619454)
9. Moretti R, Torre P, Antonello RM, Manganaro D, Vilotti C, Pizzolato G (2008) Risk factors for vascular dementia: hypotension as a key point. Vasc Health Risk Manag 4, 395-402. (Pubitemid 351711967)
10. Viswanathan A, RoccaWA, Tzourio C (2009) Vascular risk factors and dementia: how to move forward? Neurology 72, 368-374.
11. Brun A, EnglundE(1986)Awhite matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 19, 253-262. (Pubitemid 16111074)
12. Farkas E, Luiten PG (2001) Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 64, 575-611. (Pubitemid 32304447)
13. Jagust WJ (2000) Neuroimaging in dementia. Neurol Clin 18, 885-902.
14. Lee BC, Mintun M, Buckner RL, Morris JC (2003) Imaging of Alzheimer's disease. J Neuroimaging 13, 199-214. (Pubitemid 36775939)
15. Rapoport SI (2000) Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97, 5696-5698. (Pubitemid 30367459)
16. Iadecola C (2003) Atherosclerosis and neurodegeneration: unexpected conspirators in Alzheimer's dementia. Arterioscler Thromb Vasc Biol 23, 1951-1953. (Pubitemid 37433183)
17. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG (2003) Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 23, 2055-2062. (Pubitemid 37433200)
18. Mattson MP (1997) Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77, 1081-1132. (Pubitemid 27459580)
19. Christie R, Yamada M, Moskowitz M, Hyman B (2001) Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol 158, 1065-1071. (Pubitemid 32221798)
20. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias J, Goss S, Sveinbjörnsdottir S, Valdimarsson EM, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge ML, Kong A, Stefansson K, Gulcher JR (2003) The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 35, 131-138. (Pubitemid 37187631)
21. Langa KM, Foster NL, Larson EB (2004) Mixed dementia: emerging concepts and therapeutic implications. JAMA 292, 2901-2908. (Pubitemid 39628238)
22. Jellinger KA (2005) Understanding the pathology of vascular cognitive impairment. J Neurol Sci 15, 57-63. (Pubitemid 40341565)
23. KnopmanDS(2006) Dementia and cerebrovascular disease. Mayo Clin Proc 81, 223-230. (Pubitemid 43205777)
24. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28, 202-208. (Pubitemid 40445527)
25. Benarroch EE (2007) Neurovascular unit dysfunction: a vascular component of Alzheimer disease? Neurology 68, 1730-1732.
26. Lee ST, Chu K, Jung KH, Park HK, Kim DH, Bahn JJ, Kim JH, Oh MJ, Lee SK, Kim M, Roh JK (2009) Reduced circulating angiogenic cells in Alzheimer disease. Neurology 72, 1858-1863.
27. Hristov M, Erl W, Weber PC (2003) Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 23, 1185-1189. (Pubitemid 36871271)
28. Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95, 343-353. (Pubitemid 39100452)
29. Hill JM, Zalos G, Halcox JP, SchenkeWH,Waclawiw MA, Quyyumi AA, Finkel T (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348, 593-600. (Pubitemid 36204953)
30. Werner N, Kosiol S, Schiegl T, Ahlers P,Walenta K, Link A, Böhm M, Nickenig G (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353, 999-1007. (Pubitemid 41262334)
31. Kunz GA, Liang G, Cuculi F, Gregg D, Vata KC, Shaw LK, Goldschmidt-Clermont PJ, Dong C, Taylor DA, Peterson ED (2006) Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J 152, 190-195. (Pubitemid 43974737)
32. George J, Shmilovich H, DeutschV, Miller H,Keren G, Roth A (2006) Comparative analysis of methods for assessment of circulating endothelial progenitor cells. Tissue Eng 12, 331-335.
33. Erten-Lyons D,Woltjer RL, Dodge H, Nixon R, Vorobik R, Calvert JF, LeahyM,Montine T, Kaye J (2009) Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 72, 354-360.
34. Welsh-Bohmer KA, White CL 3rd (2009) Alzheimer disease: what changes in the brain cause dementia? Neurology 72, e21.
35. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191. (Pubitemid 46825511)
36. Nagata K, Maruya H, Yuya H, Terashi H, Mito Y, Kato H, Sato M, Satoh Y, Watahiki Y, Hirata Y, Yokoyama E, Hatazawa J (2000) Can PET data differentiate Alzheimer's disease from vascular dementia? Ann N Y Acad Sci 903, 252-261. (Pubitemid 30251565)
37. Grubb RL Jr, Raichle ME, Gado MH, Eichling JO, Hughes CP (1977) Cerebral blood flow, oxygen utilization and blood volume in dementia. Neurology 27, 905-910. (Pubitemid 8207161)
38. Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, Herholz K, Heiss WD (1994) HMPAO SPECT andFDGPETin Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med 21, 1052-1060. (Pubitemid 24304430)
39. Homma A, Niina R, Ishii T, Hasegawa K (1991) Behavioral evaluation of Alzheimer disease in clinical trials: development of the Japanese version of the GBS Scale. Alzheimer Dis Assoc Disord 5, 40-48.
40. Frackowiak RS, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, Jones T (1981) Regional cerebral oxygen supply and utilization in dementia. a clinical and physiological study with oxygen-15 and positron tomography. Brain 104, 753-778. (Pubitemid 12235670)
41. Tohgi H, Yonezawa H, Takahashi S, Sato N, Kato E, Kudo M, Hatano K, Sasaki T (1998) Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. Neuroradiology 40, 131-137. (Pubitemid 28438820)
42. Baron JC (1980) Human hemispheric infarction studied with positron emission tomography and the 150 continuous inhalation technique. In Computerized Tomography, Cailler JM, Salamon G, eds, Springer, Berlin, pp. 231-237.
43. Tsutsumi K, Nagata K (1998) Misery perfusion syndrome in the chronic stage of cerebral infarction. Jpn J Stroke 20, 489-499.
44. De Reuck J, Decoo D, Hasenbroekx MC, Lamont B, Santens P, Goethals P, Strijckmans K, Lemahieu I (1999) Acetazolamide vascular reactivity in vascular dementia: a positron emission tomographic study. Eur Neurol 41, 31-36. (Pubitemid 29043109)
45. De Reuck J, Santens P, Strijckmans K, Lemahieu I; EuropeanTask Force on Age-Related White Matter Changes (2001) Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes. J Neurol Sci 15, 1-6. (Pubitemid 33062388)
46. Tagliavini F, Ghiso J, Timmers WF, Giaccone G, Bugiani O, Frangione B (1990) Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab Invest 62, 761-767. (Pubitemid 20213695)
47. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ (1992) Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol 141, 249-259.
48. KondohY, Nagata K, Sasaki H, Hatazawa J (1997) Dynamic FDG-PET study in probable Alzheimer's disease. Ann N Y Acad Sci 826, 406-409. (Pubitemid 27478063)
49. de la Torre JC (2004) Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res 26, 517-524. (Pubitemid 38879234)
50. de la Torre JC, Mussivand T (1993) Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 15, 146-153. (Pubitemid 23166998)
51. Cummings JL, Benson DF (1983) Dementia, Butterworths, Boston.
52. Pluta R (2006) Is the ischemic blood-brain barrier insufficiency responsible for full-blown Alzheimer's disease? Neurol Res 28, 665-671. (Pubitemid 44433327)
53. Algotsson A, Winblad B (2007) The integrity of the bloodbrain barrier in Alzheimer's disease. Acta Neurol Scand 115, 403-408. (Pubitemid 46776325)
54. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF (2007) Blood-brain barrier impairment in Alzheimer disease. Neurology 68, 1809-1814.
55. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, Breteler MM (2005) Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 57, 789-794. (Pubitemid 40798616)
56. Qi JP, Wu H, Yang Y, Wang DD, Chen YX, Gu YH, Liu T (2007) Cerebral ischemia and Alzheimer's disease: the expression of amyliod-beta and apolipoprotein E in human ippocampus. J Alzheimers Dis 12, 335-341.
57. Marco S, Skaper SD (2006) Amyloid beta-peptide 1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett 401, 219-224. (Pubitemid 44250979)
58. Faraci FM (2005) Oxidative stress: the curse that underlies cerebral vascular dysfunction? Stroke 36, 186-188. (Pubitemid 40170778)
59. Iadecola C (1998) Cerebral circulatory dysregulation in ischemia. In Cerebrovascular Diseases, Ginsberg M, Bogousslavsky J, eds, Blackwell, Cambridge, UK, pp. 319- 332.
60. de Champlain J,Wu R, Girouard H, Karas M, El Midaoui A, Laplante MA,Wu L (2004) Oxidative stress in hypertension. Clin Exp Hypertens 26, 593-601. (Pubitemid 40129747)
61. Traystman RJ, Kirsch JR, Koehler RC (1991) Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 71, 1185-1195.
62. Malinski T (2007) Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis 11, 207-218. (Pubitemid 47018067)
63. Mazza M, Capuano A, Bria P, Mazza S (2006) Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo controlled double-blind study. Eur J Neurol 13, 981-985. (Pubitemid 44284905)
64. Markesbery WR, Carney JM(1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9, 133-146. (Pubitemid 29056524)
65. Hooijmans CR, Rutters F, Dederen PJ, Gambarota G,Veltien A, van Groen T, Broersen LM, Lütjohann D, Heerschap A, Tanila H, Kiliaan AJ (2007) Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol Dis 28, 16-29. (Pubitemid 47432903)
66. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, SmithMA(2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21, 3017-3023. (Pubitemid 32323483)
67. Chang CY, Liang HJ, Chow SY, Chen SM, Liu DZ (2007) Hemorheological mechanisms in Alzheimer's disease. Microcirculation 14, 627-634.
68. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W (2006) Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE 1 gene expression. Proc Natl Acad Sci U S A 103, 18727-18732. (Pubitemid 44913478)
69. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148, 379-397. (Pubitemid 351665469)
70. Jones RW (2003) Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? Int J Geriatr Psychiatry 18, 7-13.
71. Ringman JM, Cummings JL (2006) Current and emerging pharmacological treatment options for dementia. Behav Neurol 17, 5-16. (Pubitemid 43731791)
72. Kidd PM (2008) Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev 13, 85-115. (Pubitemid 352009500)
73. Gutzmann H, Kühl KP, Hadler D, Rapp MA (2002) Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 35, 12-18. (Pubitemid 34135453)
74. Winblad B, JonesRW,WirthY, Stöffler A, Möbius HJ (2007) Memantine in moderate to severe Alzheimer's disease: a meta analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24, 20-27. (Pubitemid 46985287)
75. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002) Molecular Biology of the Cell, 4th edn., Garland Science, New York.
76. Bartus RT, Dean RL 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-414.
77. Pauling L (1968) Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease. Science 160, 265-271.
78. AmesBN, Elson-Schwab I, SilverEA(2002) HighdoseVitamin Therapy Stimulates Variant Enzymes with Decreased Coenzyme Binding Affinity: Relevance to Genetic Disease and of the Cell, 4th edn., Garland Science, New York.
79. Kidd PM (2007) PS (PhosphatidylSerine), Nature's Brain Booster, 2nd edn., Total Health Communications, St. George, UT.
80. Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G (1993) Cognitive decline in the elderly: a double-blind, placebo controlled multicenter study on efficacy of phosphatidylserine administration. Aging 5, 123-133. (Pubitemid 23148315)
81. Kidd PM (2007) GPC (GlyceroPhosphoCholine), Mind- Body Power for Active Living and Healthy Aging, Total Health Communications, St. George, UT.
82. De Jesus Moreno MorenoM(2003) Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther 25, 178-193. (Pubitemid 36206745)
83. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F (2007) Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J Neurol Sci 257, 264-269. (Pubitemid 46856504)
84. Ciriaco E, Bronzetti E, Ricci A, Amenta F (1994) Influence of ipsilateral lesions of the nucleus basalis magnocellularis and of choline alphoscerate treatment on histochemically reactive zinc stores and on the ultrastructure of the rat frontal cortex. Arch Gerontol Geriatr 19, 303-312.
85. Montgomery SA, Thal LJ, Amrein R (2003) Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 18, 61-71. (Pubitemid 36343974)
86. Angelucci L, Ramacci MT, Taglialatela G, Hulsebosch C, Morgan B, Werrbach-Perez K, Perez-Polo R (1988) Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neurosci Res 20, 491-496.
87. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42, 776-782. (Pubitemid 27481550)
88. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60, 940-946. (Pubitemid 36858352)
89. Kyle DJ, Schaefer E, Patton G, Beiser A (1999) Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 34, S245. (Pubitemid 29323210)
90. Conquer JA, TierneyMC, Zecevic J, Bettger WJ, Fisher RH (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35, 1305-1312. (Pubitemid 32064179)
91. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Azheimer's disease: a case-control study. Br J Nutr 89, 483-489. (Pubitemid 36582118)
92. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63, 1402-1408. (Pubitemid 44547551)
93. Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jönhagen M (2008) Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23, 161-169. (Pubitemid 351308496)
94. Corrigan FM, Van Rhijn A, Horrobin DF (1991) Essential fatty acids in Alzheimer's disease. Ann N Y Acad Sci 640, 250-252.
95. Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R (1999) Double-blind placebocontrolled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol 21, 633-644. (Pubitemid 30033075)
96. Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bartorelli L, Bordin A, Crepaldi G, Cristianini G, Cucinotta D, Cuzzupoli M, De Candia O, Fabris F, Maggioni M, Scarpa R, Villardita C, Girardello R, Poli A, Senin U (1995) Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid. Acta Neurol Scand 92, 135-140.
97. Fioravanti M, Yanagi M (2005) Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 18(2), CD000269.
98. Snowdon D (2002) Aging with Grace: What the Nun Study Teaches us About Leading Longer, Healthier, and More Meaningful Lives, Bantam Books, New York, NY, pp. 357- 359.
99. Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC (2007) Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo controlled study in Taiwanese patients. Clin Ther 29, 2204-2214. (Pubitemid 350138567)
100. Miller AL (2003) The methionine-homocysteine cycle and its effects on cognitive diseases. Altern Med Rev 8, 7-19. (Pubitemid 36330564)
101. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA (2006) Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 59, 912-921. (Pubitemid 43830923)
102. Oken BS, Storzbach DM, Kaye JA (1998) The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 55, 1409-1415. (Pubitemid 28525500)
103. Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R (2002) Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology 45, 19-26. (Pubitemid 34117724)
104. Le Bars PL (2003) Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry 36, 50-55.
105. Napryeyenko O, Borzenko I; GINDEM-NP Study Group (2007) Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 57, 4-11. (Pubitemid 46212982)
106. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 278, 1327-1332. (Pubitemid 27449692)
107. Indena C (2004) Ginkgoselect Phytosome: Bioavailable Standardized Extract of Ginkgo Biloba Leaves, Indena USA Inc., Seattle, WA.
108. Miller Al, Dover ID (2002) Ginkgo biloba. In Alternative Medicine ReviewMonographs, Thorne Research, Miller AL, Dover, ID, pp. 168-174.
109. Wolf HR (2006) Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicyclic acid 500 mg daily? Drugs R D 7, 163-172. (Pubitemid 43890711)
110. Carlson JJ, Farquhar JW, DiNucci E, Ausserer L, Zehnder J, Miller D, Berra K, Hagerty L, HaskellWL(2007) Safety and efficacy of a Ginkgo biloba-containing dietary supplement on cognitive function, quality of life, and platelet function in healthy, cognitively intact older adults. J Am Diet Assoc 107, 422-432. (Pubitemid 46281825)
111. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H; GuidAge Study Group (2006) The GuidAge Study: methodological issues. A 5-year doubleblind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 67, 6-11.
112. Shankle WR, Amen DG (2004) Preventing Alzheimer's, G.P. Putnam's Sons, New York, NY, pp. 112-116.
113. Rinker T (2008) The Renegade Patient: A Smart, User- Friendly Guide to Effective Healthcare, Biomed Publishing, South LakeTahoe, CA, pp. 57-59.
114. Rowe JW, Khan RL (1999) Successful Aging, Dell Publishing, New York, NY, pp. 78-88.
115. Drachman DA (2006) Aging of the brain, entropy, and Alzheimer disease. Neurology 67, 1340-1352. (Pubitemid 44632055)
116. Black JE, Isaacs KR, Greenough WT (1991) Usual vs. successful aging: some notes on experiential factors. Neurobiol Aging 12, 325-328.
117. Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, Kryscio RJ (2007) Transitions to mild cognitive impairment, dementia, and death: findings from the Nun Study. Am J Epidemiol 165, 1231-1238. (Pubitemid 47234333)
118. Alzheimer's Association (2008) Alzheimer's Disease Facts and Figure, Available at: http://www.alz.org/, Accessed March 15, 2008.
119. Swaab DF (1991) Brain aging and Alzheimer's disease, "wear and tear" versus "use it or lose it". Neurobiol Aging 12, 317-324.
120. Sabbagh MN (2008) The Alzheimer's Answer: Reduce Your Risk and Keep Your Body Healthy, John Wiley & Sons, Hoboken, NJ, pp. 66-67.
121. Bower B (2006) Grown-up connections. Mice, monkeys remake brain links as adults. Sci News 6, 169-165.
122. Doidge N (2007) The Brain That Changes Itself. Viking (Penguin Group), New York, NY, pp. 161-168.
123. Gatz M (2005) Educating the brain to avoid dementia: can mental exercise prevent Alzheimer disease? PLoS Med 2, 38-40.
124. Grant W (2005) Accounting for individual differences in risk of Alzheimer disease. PLoS Med 2 e82, 262-267.
125. Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider- Beeri M (2005) Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry 62, 565-573. (Pubitemid 40628886)
126. Nelson LD (2007) An experimental approach to detecting dementia in Down syndrome: a paradigm for Alzheimer's disease. Brain Cogn 64, 92-103. (Pubitemid 46805116)
127. Pennington BF, Moon J, Edgin J, Stedron J, Nadel L (2003) The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev 74, 75-93. (Pubitemid 37244589)
128. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, MullanM(1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844-846. (Pubitemid 21912637)
129. Jellinger KA (2004) Head injury and dementia. Curr Opin Neurol 17, 719-723. (Pubitemid 39613004)
130. Anstey KJ, von Sanden C, Salim A, O'Kearney R (2007) Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 166, 367-378. (Pubitemid 47216800)
131. Sabbagh MN, Tyas SL, Emery SC, Hansen LA, Alford MF, Reid RT, Tiraboschi P, Thal LJ (2005) Smoking affects the phenotype of Alzheimer disease. Neurology 64, 1301-1303.
132. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer's disease. Arch Intern Med 163, 1524-1528. (Pubitemid 36835095)
133. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330, 1360-1365.
134. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA,MarkesberyWR(1997) Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA 277, 813-817. (Pubitemid 27111317)
135. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ (2000) Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 21, 49-55. (Pubitemid 30224785)
136. Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD (2008) Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 178, 548-556. (Pubitemid 351413998)
137. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483. (Pubitemid 34441738)
138. Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Jacques PF, Selhub J, Seshadri S, Au R, Beiser A, Wolf PA (2005) Homocysteine and cognitive performance in the Framingham Offspring Study: age is important. Am J Epidemiol 162, 644-653. (Pubitemid 41437363)
139. Luchsinger JA, Tang MX, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192. (Pubitemid 39350015)
140. Cole GM, Frautschy SA (2007) The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp Gerontol 42, 10-21. (Pubitemid 44937832)
141. Taguchi A (2009) Vascular factors in diabetes and Alzheimer's disease. J Alzheimers Dis 16, 859-864.
142. Kidd PM (2000) Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev 5, 502-529. (Pubitemid 32104062)
143. Yokel RA (2006) Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J Alzheimers Dis 10, 223-253. (Pubitemid 44763995)
144. Ritchie KA, Gilmour WH, Macdonald EB, Burke FJ, McGowan DA, Dale IM, Hammersley R, Hamilton RM, Binnie V, Collington D (2002) Health and neuropsychological functioning of dentists exposed to mercury. Occup Environ Med 59, 287-293. (Pubitemid 34496840)
145. Shcherbatykh I, Carpenter DO (2007) The role of metals in the etiology of Alzheimer's disease. J Alzheimers Dis 11, 191-205. (Pubitemid 47010984)
146. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F (2005) Relation of C-reactive protein to stroke, cognitive disorders and depression in the general population: systematic review and meta-analysis. Lancet Neurol 4, 371-380. (Pubitemid 40720034)
147. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ (2002) Early inflammation and dementia: a 25- year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 52, 168-174. (Pubitemid 34810596)
148. Trembath D, Ervin JF, Broom L, Szymanski M, Welsh- Bohmer K, Pieper C, Hulette CM (2007) The distribution of cerebrovascular amyloid in Alzheimer's disease varies with ApoE genotype. Acta Neuropathol 113, 23-31. (Pubitemid 44782926)
149. Frenkel D, Farfara D, Lifshitz V (2008) Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 12, 762-780. (Pubitemid 351718063)
150. Breteler MM, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, Rocca WA, Shalat SL, Soininen H, Hofman A (1991) Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20, 36-42.
151. de Jong FJ, den Heijer T, Visser TJ, de Rijke YB, Drexhage HA, Hofman A, Breteler MM (2006) Thyroid hormones, dementia, and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 91, 2569-2573. (Pubitemid 44024619)
152. Labudova O, Cairns N, Koeck T, Kitzmueller E, Rink H, Lubec G (1999) Thyroid stimulating hormone-receptor overexpression in brain of patients with Down syndrome and Alzheimer's disease. Life Sci 64, 1037-1044. (Pubitemid 29130562)
153. Davanipour Z, Tseng CC, Lee PJ, Sobel E (2007) A case-control study of occupational magnetic field exposure and Alzheimer's disease: results from the California Alzheimer's disease diagnosis and Treatment centers. BMC Neurol 7, 13-22.
154. McCarty MF (2006) Toward prevention of Alzheimers disease-potential nutraceutical strategies for suppressing the production of amyloid beta peptides. Med Hypotheses 67, 682-697. (Pubitemid 44062158)